Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

Increased mucosal expression of miR-215 precedes the development of neoplasia in patients with long-standing ulcerative colitis.

Pekow J, Meckel K, Dougherty U, Haider HI, Deng Z, Hart J, Rubin DT, Bissonnette M.

Oncotarget. 2018 Apr 17;9(29):20709-20720. doi: 10.18632/oncotarget.25065. eCollection 2018 Apr 17.

2.

Efficacy and Follow-up of Sub-Total Colectomy With Ileo-Rectal Anastomoses in Patients With Colitis-associated Neoplasia.

Cleveland NK, Ollech JE, Colman RJ, Rodriquez D, Hirsch A, Cohen RD, Hanauer SB, Hart J, Hurst R, Rubin DT.

Clin Gastroenterol Hepatol. 2018 May 8. pii: S1542-3565(18)30467-1. doi: 10.1016/j.cgh.2018.04.061. [Epub ahead of print] No abstract available.

PMID:
29751167
3.

Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.

Christensen B, Gibson P, Micic D, Colman RJ, Goeppinger SR, Kassim O, Yarur A, Weber CR, Cohen RD, Rubin DT.

Clin Gastroenterol Hepatol. 2018 May 8. pii: S1542-3565(18)30466-X. doi: 10.1016/j.cgh.2018.04.060. [Epub ahead of print]

PMID:
29751166
4.

Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey.

Yarlas A, Rubin DT, Panés J, Lindsay JO, Vermeire S, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, DiBonaventura M.

J Crohns Colitis. 2018 Apr 27;12(5):600-609. doi: 10.1093/ecco-jcc/jjy024.

PMID:
29718244
5.

The use of tofacitinib in the treatment of inflammatory bowel disease.

Weisshof R, Golan MA, Yvellez OV, Rubin DT.

Immunotherapy. 2018 Apr 27. doi: 10.2217/imt-2018-0015. [Epub ahead of print]

PMID:
29701124
6.

Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis.

Colman RJ, Lawton RC, Dubinsky MC, Rubin DT.

Inflamm Bowel Dis. 2018 Apr 23. doi: 10.1093/ibd/izy078. [Epub ahead of print]

PMID:
29688409
7.

Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.

Christensen B, Gibson PR, Rubin DT.

Aliment Pharmacol Ther. 2018 May;47(10):1423-1424. doi: 10.1111/apt.14638. No abstract available.

PMID:
29676007
8.

The New Frontier: the Intestinal Microbiome and Surgery.

Skowron KB, Shogan BD, Rubin DT, Hyman NH.

J Gastrointest Surg. 2018 Apr 9. doi: 10.1007/s11605-018-3744-7. [Epub ahead of print]

PMID:
29633119
9.

Identification of Endpoints for Development of Anti-fibrosis Drugs for Treatment of Crohn's Disease.

Danese S, Bonovas S, Lopez A, Fiorino G, Sandborn WJ, Rubin DT, Kamm MA, Colombel JF, Sands BE, Vermeire S, Panes J, Rogler G, D'Haens G, Peyrin-Biroulet L.

Gastroenterology. 2018 Mar 27. pii: S0016-5085(18)30339-1. doi: 10.1053/j.gastro.2018.03.032. [Epub ahead of print]

PMID:
29601825
10.

Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.

Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT.

Inflamm Bowel Dis. 2018 Mar 19;24(4):849-860. doi: 10.1093/ibd/izx067.

PMID:
29562271
11.

Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy.

Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen RD, Pekow J.

Inflamm Bowel Dis. 2018 Mar 1. doi: 10.1093/ibd/izx105. [Epub ahead of print]

PMID:
29506124
12.

Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2.

Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J, Lasch K.

J Crohns Colitis. 2018 Apr 27;12(5):621-626. doi: 10.1093/ecco-jcc/jjy019.

PMID:
29471381
13.

Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.

Mak WY, Buisson A, Andersen MJ Jr, Lei D, Pekow J, Cohen RD, Kahn SA, Pereira B, Rubin DT.

Dig Dis Sci. 2018 May;63(5):1294-1301. doi: 10.1007/s10620-018-4980-0. Epub 2018 Feb 22.

PMID:
29468374
14.

The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.

Yamada A, Komaki Y, Patel N, Komaki F, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A.

Inflamm Bowel Dis. 2018 Feb 15;24(3):502-509. doi: 10.1093/ibd/izx054.

PMID:
29462385
15.

Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study.

Micic D, Yarur A, Gonsalves A, Rao VL, Broadaway S, Cohen R, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT.

Dig Dis Sci. 2018 Apr;63(4):1016-1024. doi: 10.1007/s10620-018-4941-7. Epub 2018 Feb 8.

PMID:
29417331
16.

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.

Christensen B, Micic D, Gibson PR, Yarur A, Bellaguarda E, Corsello P, Gaetano JN, Kinnucan J, Rao VL, Reddy S, Singh S, Pekow J, Rubin DT.

Aliment Pharmacol Ther. 2018 Mar;47(6):753-762. doi: 10.1111/apt.14525. Epub 2018 Jan 29.

PMID:
29377235
17.

Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease.

Krugliak Cleveland N, Huo D, Sadiq F, Sofia MA, Marks J, Cohen RD, Hanauer SB, Turner J, Hart J, Rubin DT.

Gastrointest Endosc. 2018 May;87(5):1304-1309. doi: 10.1016/j.gie.2017.12.016. Epub 2018 Jan 4.

PMID:
29307473
18.

Recent Research on Joint Pain and Arthritis in Patients With Inflammatory Bowel Disease.

Rubin DT.

Gastroenterol Hepatol (N Y). 2017 Nov;13(11):688-690. No abstract available.

19.

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.

Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT.

J Crohns Colitis. 2018 Jan 24;12(2):145-156. doi: 10.1093/ecco-jcc/jjx133.

20.

Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors.

Gibofsky A, Skup M, Mittal M, Johnson SJ, Davis M, Chao J, Rubin DT.

Curr Med Res Opin. 2017 Nov;33(11):1945-1953. doi: 10.1080/03007995.2017.1375903. Epub 2017 Sep 21.

PMID:
28870101
21.

Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease.

Micic D, Gaetano JN, Rubin JN, Cohen RD, Sakuraba A, Rubin DT, Pekow J.

PLoS One. 2017 Aug 24;12(8):e0182900. doi: 10.1371/journal.pone.0182900. eCollection 2017.

22.

Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon.

Krugliak Cleveland N, Rubin DT, Hart J, Weber CR, Meckel K, Tran AL, Aelvoet AS, Pan I, Gonsalves A, Gaetano JN, Williams KM, Wroblewski K, Jabri B, Pekow J.

Clin Gastroenterol Hepatol. 2018 Jan;16(1):68-74. doi: 10.1016/j.cgh.2017.07.023. Epub 2017 Jul 26.

PMID:
28756053
23.

Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.

Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M.

J Manag Care Spec Pharm. 2017 Aug;23(8):859-867. doi: 10.18553/jmcp.2017.16272. Epub 2017 Mar 15.

24.

Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies.

Micic D, Komaki Y, Alavanja A, Rubin DT, Sakuraba A.

J Clin Gastroenterol. 2017 Jul 21. doi: 10.1097/MCG.0000000000000865. [Epub ahead of print]

PMID:
28737645
25.

Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases.

Yarur AJ, Gondal B, Hirsch A, Christensen B, Cohen RD, Rubin DT.

J Clin Gastroenterol. 2017 Jul 18. doi: 10.1097/MCG.0000000000000889. [Epub ahead of print]

PMID:
28723860
26.

Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab.

Yamada A, Komaki Y, Patel N, Komaki F, Aelvoet AS, Tran AL, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A.

Am J Gastroenterol. 2017 Sep;112(9):1423-1429. doi: 10.1038/ajg.2017.201. Epub 2017 Jul 18.

PMID:
28719595
27.

miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD.

Pekow J, Meckel K, Dougherty U, Huang Y, Chen X, Almoghrabi A, Mustafi R, Ayaloglu-Butun F, Deng Z, Haider HI, Hart J, Rubin DT, Kwon JH, Bissonnette M.

Clin Cancer Res. 2017 Sep 1;23(17):5281-5291. doi: 10.1158/1078-0432.CCR-17-0171. Epub 2017 Jun 9.

PMID:
28600480
28.

miR-4728-3p Functions as a Tumor Suppressor in Ulcerative Colitis-associated Colorectal Neoplasia Through Regulation of Focal Adhesion Signaling.

Pekow J, Hutchison AL, Meckel K, Harrington K, Deng Z, Talasila N, Rubin DT, Hanauer SB, Hurst R, Umanskiy K, Fichera A, Hart J, Dinner AR, Bissonnette M.

Inflamm Bowel Dis. 2017 Aug;23(8):1328-1337. doi: 10.1097/MIB.0000000000001104.

PMID:
28594651
29.

Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Paramsothy S, Paramsothy R, Rubin DT, Kamm MA, Kaakoush NO, Mitchell HM, Castaño-Rodríguez N.

J Crohns Colitis. 2017 Oct 1;11(10):1180-1199. doi: 10.1093/ecco-jcc/jjx063.

PMID:
28486648
30.

Tracking microbial colonization in fecal microbiota transplantation experiments via genome-resolved metagenomics.

Lee STM, Kahn SA, Delmont TO, Shaiber A, Esen ÖC, Hubert NA, Morrison HG, Antonopoulos DA, Rubin DT, Eren AM.

Microbiome. 2017 May 4;5(1):50. doi: 10.1186/s40168-017-0270-x.

31.

Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.

Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP.

J Crohns Colitis. 2017 Dec 4;11(12):1510. doi: 10.1093/ecco-jcc/jjx052. No abstract available.

32.

The Drivers of Discretionary Utilization: Clinical History Versus Physician Supply.

Ruhnke GW, Manning WG, Rubin DT, Meltzer DO.

Acad Med. 2017 May;92(5):703-708. doi: 10.1097/ACM.0000000000001500.

33.

Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States.

Patel H, Lissoos T, Rubin DT.

PLoS One. 2017 Apr 20;12(4):e0175099. doi: 10.1371/journal.pone.0175099. eCollection 2017.

34.

Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.

O'Donnell PH, Wadhwa N, Danahey K, Borden BA, Lee SM, Hall JP, Klammer C, Hussain S, Siegler M, Sorrentino MJ, Davis AM, Sacro YA, Nanda R, Polonsky TS, Koyner JL, Burnet DL, Lipstreuer K, Rubin DT, Mulcahy C, Strek ME, Harper W, Cifu AS, Polite B, Patrick-Miller L, Yeo KT, Leung E, Volchenboum SL, Altman RB, Olopade OI, Stadler WM, Meltzer DO, Ratain MJ.

Clin Pharmacol Ther. 2017 Nov;102(5):859-869. doi: 10.1002/cpt.709. Epub 2017 Jun 15.

PMID:
28398598
35.

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.

Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP.

J Crohns Colitis. 2017 Jul 1;11(7):785-791. doi: 10.1093/ecco-jcc/jjx032.

36.

Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician Visits.

Rubin DT, Dubinsky MC, Martino S, Hewett KA, Panés J.

Inflamm Bowel Dis. 2017 Apr;23(4):494-501. doi: 10.1097/MIB.0000000000001048.

37.

Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes.

Christensen B, Hanauer SB, Erlich J, Kassim O, Gibson PR, Turner JR, Hart J, Rubin DT.

Clin Gastroenterol Hepatol. 2017 Oct;15(10):1557-1564.e1. doi: 10.1016/j.cgh.2017.02.016. Epub 2017 Feb 24.

PMID:
28238954
38.

Early Transcriptomic Changes in the Ileal Pouch Provide Insight into the Molecular Pathogenesis of Pouchitis and Ulcerative Colitis.

Huang Y, Dalal S, Antonopoulos D, Hubert N, Raffals LH, Dolan K, Weber C, Messer JS, Jabri B, Bendelac A, Eren AM, Rubin DT, Sogin M, Chang EB.

Inflamm Bowel Dis. 2017 Mar;23(3):366-378. doi: 10.1097/MIB.0000000000001027.

PMID:
28221248
39.

The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions.

Sofia MA, Rubin DT.

Dig Dis Sci. 2017 Apr;62(4):833-842. doi: 10.1007/s10620-017-4479-0. Review.

PMID:
28197743
40.

Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay.

Rubin DT, Naik S, Kondragunta V, Rao T, Jain A.

Curr Med Res Opin. 2017 May;33(5):837-843. doi: 10.1080/03007995.2017.1289908. Epub 2017 Mar 2.

PMID:
28145781
41.

Two Complex Cases of Hermansky-Pudlak Syndrome Highlight a Potential Biologic Explanation for an Associated Crohn's Disease Phenotype.

Sofia MA, Sakuraba A, Rubin DT.

ACG Case Rep J. 2017 Jan 18;4:e14. doi: 10.14309/crj.2017.14. eCollection 2017.

42.

The Role of Biosimilars in Inflammatory Bowel Disease.

Paramsothy S, Cleveland NK, Zmeter N, Rubin DT.

Gastroenterol Hepatol (N Y). 2016 Dec;12(12):741-751.

43.

The Crohn's and Colitis Foundation of America Survey of Inflammatory Bowel Disease Patient Health Care Access.

Rubin DT, Feld LD, Goeppinger SR, Margolese J, Rosh J, Rubin M, Kim S, Rodriquez DM, Wingate L.

Inflamm Bowel Dis. 2017 Feb;23(2):224-232. doi: 10.1097/MIB.0000000000000994.

PMID:
27997434
44.

Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program.

McKillip RP, Borden BA, Galecki P, Ham SA, Patrick-Miller L, Hall JP, Hussain S, Danahey K, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreuer K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, Stadler WM, Ratain MJ, Meltzer DO, O'Donnell PH.

Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.586. [Epub ahead of print]

PMID:
27981566
45.

Patient-Specific Bacteroides Genome Variants in Pouchitis.

Vineis JH, Ringus DL, Morrison HG, Delmont TO, Dalal S, Raffals LH, Antonopoulos DA, Rubin DT, Eren AM, Chang EB, Sogin ML.

MBio. 2016 Nov 15;7(6). pii: e01713-16. doi: 10.1128/mBio.01713-16.

46.

Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease.

Siva S, Rubin DT, Gulotta G, Wroblewski K, Pekow J.

Inflamm Bowel Dis. 2017 Jan;23(1):152-157. doi: 10.1097/MIB.0000000000000989.

47.

Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis.

Rubin DT, Patel H, Shi S, Mody R.

Curr Med Res Opin. 2017 Mar;33(3):529-536. doi: 10.1080/03007995.2016.1267616. Epub 2017 Jan 12.

PMID:
27903084
48.

Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.

Feagan BG, Patel H, Colombel JF, Rubin DT, James A, Mody R, Lasch K.

Aliment Pharmacol Ther. 2017 Jan;45(2):264-275. doi: 10.1111/apt.13852. Epub 2016 Nov 17.

49.

Outcomes of colitis-associated dysplasia after referral from the community to a tertiary center.

Rubin DT, Krugliak Cleveland N, Rodriquez DM.

Gastrointest Endosc. 2016 Dec;84(6):1078-1079. doi: 10.1016/j.gie.2016.04.026. No abstract available.

PMID:
27855794
50.

When Subjects Violate the Research Covenant: Lessons Learned from a Failed Clinical Trial of Fecal Microbiota Transplantation.

Kahn SA, Rubin DT.

Am J Gastroenterol. 2016 Nov;111(11):1508-1510. doi: 10.1038/ajg.2016.153. Epub 2016 May 10. No abstract available.

PMID:
27166127

Supplemental Content

Loading ...
Support Center